Novotech beefs up Asia-Pacific CRO offering with new buyout as region’s biopharma business booms
→ Asia-Pacific CRO Novotech is expanding, buying out CRO Clinical Network Services as it builds up its early- to late-stage trial network in the region.
CNS’ 140 staffers in Australia, New Zealand and the US will continue to operate as an independent unit, working with the 400 staffers at Novotech in the Asia-Pacific region. No terms were provided.
CNS specializes in early phase non-oncology clinical trials across Australia and New Zealand, with Novotech specializing in “regional Asia-Pacific and global project delivery across all phases.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.